DDX53 and neoplasm: To assess the anti-proliferative effect of the association between RT and MRTX1257 in CT26 KRASG12C+/+ and CT26 WT tumors, we performed immunohistochemistry (IHC) analyses in both tumor types the day after the last administration of MRTX1257, i.e. D4 after RT (Fig. 5A).